A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although it says studies aimed at getting US approval are on track to ...

Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data ...

Data presented at the 2024 Society of Hematologic Oncology (SOHO) Annual Meeting showed that irrespective of whether patients were treated with a BTK inhibitor in the first or second line, the ...

suggesting potential benefits of BTK inhibitors in treating conditions such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, allergies, and asthma.

Half of patients with Richter transformation responded to the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) ...

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet ...